Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Nucala (mepolizumab)
pCPA File Number:
20946
Negotiation Status:
Concluded with an LOI
Indication(s):
Severe Eosinophilic Asthma
Sponsor/Manufacturer:
GlaxoSmithKline
CADTH Project Number:
SR0461-000
pCPA Engagement Letter Issued:
2016-10-21
Negotiation Process Concluded:
2017-11-24